Table 3.
Baseline demographics and clinical characteristics
| Characteristic | Vismodegib 150 mg/day + pirfenidone ≤ 2403 mg/day (N = 21) |
|---|---|
| Age, mean (SD), years | 70.6 (6.8) |
| Male, n (%) | 19 (90.5) |
| White, n (%) | 19 (90.5) |
| BMI, mean (SD), kg/m2 | 28.93 (3.27) |
| Time from IPF diagnosis, mean (SD), years | 2.45 (1.37) |
| Smoking status, n (%) | |
| Never | 3 (14.3) |
| Former | 18 (85.7) |
| Current | 0 |
| FVC, mean (SD), % predicted | 67.38 (13.29) |
| DLco, mean (SD), % predicteda | 62.79 (24.13) |
| UCSD-SOBQ score, mean (SD) | 48.62 (22.49) |
BMI body mass index, DLco diffusing capacity for carbon monoxide, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, SD standard deviation, UCSD-SOBQ University of California, San Diego Shortness of Breath Questionnaire
aCorrected for alveolar volume and hemoglobin